Conjugating Existing Clinical Drugs With Gold Nanoparticles for Better Treatment of Heart Diseases
Open Access
- 29 May 2018
- journal article
- review article
- Published by Frontiers Media SA in Frontiers in Physiology
- Vol. 9, 642
Abstract
Developing new methods to treat heart diseases is always a focus for basic research and clinical applications. Existing drugs have strong side-effects and also require lifetime administration for patients. Recent attempts of using nanoparticles (NPs) in treating atherosclerosis in animals and some heart diseases such as heart failure and endocarditis have provided hopes for better drug delivery and reducing of drug side-effects. In this mini-review, we summarize the present applications of using gold nanoparticles (GNPs) as a new drug delivery system in diseased hearts and of the assessment of toxicity in using GNPs. We suggest that conjugating existing clinical drugs with GNPs is a favorable choice to provide “new and double-enhanced” potentiality to those existing drugs in treating heart diseases. Other applications of using NPs in the treatment of heart diseases including using drugs in nano-form and coating drugs with a surface of relevant NP are also discussed.Keywords
This publication has 22 references indexed in Scilit:
- Distribution of Systemically Administered Nanoparticles Reveals a Size-Dependent Effect Immediately following Cardiac Ischaemia-Reperfusion InjuryScientific Reports, 2016
- Gold nanoparticles alter parameters of oxidative stress and energy metabolism in organs of adult ratsBiochemistry and Cell Biology, 2015
- Differential hERG ion channel activity of ultrasmall gold nanoparticlesProceedings of the National Academy of Sciences, 2013
- Gold nanoparticles administration induces disarray of heart muscle, hemorrhagic, chronic inflammatory cells infiltrated by small lymphocytes, cytoplasmic vacuolization and congested and dilated blood vesselsLipids in Health and Disease, 2011
- Exposure to gold nanoparticles produces cardiac tissue damage that depends on the size and duration of exposureLipids in Health and Disease, 2011
- Time Evolution of the Nanoparticle Protein CoronaACS Nano, 2010
- Size-dependent tissue kinetics of PEG-coated gold nanoparticlesToxicology and Applied Pharmacology, 2010
- Interaction of Gold Nanoparticles with Common Human Blood ProteinsACS Nano, 2009
- Gold nanoparticles in delivery applications☆Advanced Drug Delivery Reviews, 2008
- Particle size-dependent organ distribution of gold nanoparticles after intravenous administrationBiomaterials, 2008